Home
>
US Stocks
>
Adc Therapeutics SA
Adc Therapeutics SA
ADCT

Adc Therapeutics SA

$25.6310.07%

1D

1W

1M

1Y

3Y

5Y

Key Stats

Open
25.08
Today Low/High
25.08 / 26.08
52 Week Low/High
$20.01 / $47
Market Cap
$2.09B

Company Details

ADC Therapeutics SA is a late clinical-stage oncology-focused biotechnology company pioneering the development and commercialization of potent and targeted antibody drug conjugates (ADCs) for patients with hematological malignancies and solid tumors. The Company has created a deep clinical pipeline by combining its decades of experience and strategic target selection with proprietary next-generation pyrrolobenzodiazepine (PBD) technology. The Company's Biologics License Application for its lead product candidate, loncastuximab tesirine (Lonca, formerly ADCT-402) for the treatment of relapsed or refractory diffuse large B-cell lymphoma was given priority review status by the U.S. Food and Drug Administration and a Prescription Drug User Fee Act (PDUFA) target date of May 21, 2021. The Company's second lead product candidate, camidanlumab tesirine (Cami, formerly ADCT-301), is being evaluated in a 117-patient pivotal Phase 2 clinical trial for the treatment of relapsed or refractory Hodgkin lymphoma.
Organisation
Adc Therapeutics SA
Employees
208
Industry
Health Technology

Discover more

Frequently Asked Questions

What is Adc Therapeutics SA share price today

Can Indians buy Adc Therapeutics SA shares?

How can I buy Adc Therapeutics SA shares from India?

Can Fractional shares of Adc Therapeutics SA be purchased?

What are the documents required to start investing in Adc Therapeutics SA stocks?

We are a SEBI registered investement advisor